Replies to post #2087 on Enanta Pharmaceuticals Inc (ENTA)

[vinmantoo]

The hit to the share price ought to be pretty modest inasmuch as EDP-721 was only in phase-1.

That is what I was guessing but who knows.

The question, of course, is whether the safety problem seen with EDP-721 is compound-specific or class-specific.

I assume the FDA will be extremely cautious with any RNA destabilizer of this class. I sure hope ENTA has other HepB targets in mind. Do you think ENTA will advance EDP-514 in trials in combination with a nuc, at least for now?